Recce Pharmaceuticals Ltd (ASX:RCE)
Australia · Delayed Price · Currency is AUD 0.3550
-0.0050 (-1.39%)
Sep 2, 2026, 1:32 PM AEST
Recce Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 9.94 | 7.51 | 5.03 | 4.37 | 3.08 |
| 9.94 | 7.51 | 5.03 | 4.37 | 3.08 | |
Revenue Growth | 32.37% | 49.33% | 15.19% | 41.50% | 88.41% |
Cost of Revenue | 8.15 | 10.45 | 7.22 | 7.41 | 6.33 |
Gross Profit | 1.79 | -2.94 | -2.19 | -3.05 | -3.25 |
Selling, General & Admin | 8.08 | 8.36 | 7.09 | 5.75 | 3.54 |
Amortization of Goodwill & Intangibles | - | - | - | - | 0.14 |
Other Operating Expenses | 5.58 | 7.41 | 7.33 | 3.53 | 2.42 |
Operating Expenses | 15.09 | 17.47 | 14.81 | 9.83 | 6.4 |
Operating Income | -13.3 | -20.41 | -17 | -12.88 | -9.65 |
Interest Expense | -1.66 | -1.21 | -0.84 | -0.18 | -0.01 |
Interest & Investment Income | - | 0.11 | 0.19 | 0.07 | 0.09 |
Currency Exchange Gain (Loss) | - | 0.13 | -0 | - | - |
Other Non Operating Income (Expenses) | - | -0.05 | -0.01 | -0.01 | -0 |
EBT Excluding Unusual Items | -14.96 | -21.43 | -17.66 | -12.99 | -9.57 |
Legal Settlements | - | - | - | -0.08 | -1.42 |
Pretax Income | -14.96 | -21.43 | -17.66 | -13.08 | -10.99 |
Net Income | -14.96 | -21.43 | -17.66 | -13.08 | -10.99 |
Net Income to Common | -14.96 | -21.43 | -17.66 | -13.08 | -10.99 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 289 | 237 | 177 | 174 | 174 |
Shares Outstanding (Diluted) | 289 | 237 | 177 | 174 | 174 |
Shares Change | 22.12% | 33.81% | 1.79% | -0.09% | 12.05% |
EPS (Basic) | -0.05 | -0.09 | -0.10 | -0.08 | -0.06 |
EPS (Diluted) | -0.05 | -0.09 | -0.10 | -0.08 | -0.06 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -9.95 | -20.47 | -13.15 | -12.73 | -9.05 |
Free Cash Flow Per Share | -0.03 | -0.09 | -0.07 | -0.07 | -0.05 |
Gross Margin | 17.99% | -39.12% | -43.52% | -69.83% | -105.22% |
Operating Margin | -133.84% | -271.76% | -338.04% | -295.00% | -312.74% |
Profit Margin | -150.53% | -285.37% | -351.24% | -299.58% | -356.12% |
Free Cash Flow Margin | -100.15% | -272.59% | -261.53% | -291.53% | -293.38% |
EBITDA | -13.23 | -20.33 | -16.93 | -12.83 | -9.6 |
EBITDA Margin | -133.15% | -270.81% | - | -293.92% | - |
D&A For EBITDA | 0.07 | 0.07 | 0.07 | 0.05 | 0.05 |
EBIT | -13.3 | -20.41 | -17 | -12.88 | -9.65 |
EBIT Margin | -133.84% | -271.76% | - | -295.00% | - |
Advertising Expenses | 0.82 | 1.24 | 1.24 | 1.12 | 0.99 |